Zhoumengze

1、Educational Experience

  2019.09 - 2022.06  China pharmaceutical university  Ph.D

  2016.09 - 2019.06  Nanjing Medical University  Master

  2010.09 - 2014.06  China pharmaceutical university  Bachelor

2、Working Experience

  2022.06 - Now  China pharmaceutical university-Department of Pharmacology

1. Zhou M^#, Liu C^#, Guo Y, et al. HQL6 serves as a novel P2Y14 receptor antagonist to ameliorate acute gouty arthritis through inhibiting macrophage pyroptosis. Int Immunopharmacol. 2023, 114: 109507.(IF = 5.714)

2. Zhou M^#, Wang W^#, Wang Z, et al. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y₁₄R antagonists with anti-gout potential. Eur J Med Chem. 2022, 227: 113933.

3. Zhou M^#, Wang W^#, Li Y, et al. The role of P2Y₆R in cardiovascular diseases and recent development of P2Y₆R antagonists. Drug Discov Today. 2020, 25(3): 568-573. (IF= 7.321)

4. 

5. Zhou M^#, Li S, Song L,et al. 4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3. Phytomedicine. 2018, 42: 9-17.

6. Wang Y^#, Zhou M^#, Ye T, et al. Discovery of a Series of 5-Amide1H-pyrazole-3-carboxyl Derivatives as Potent P2Y14R Antagonists with Anti-Inflammatory Characters, Journal of Medicinal Chemistry, 2022, 65(23): 15967-15990

7. Liu C^#, Zhou M^#, Jiang W, et al. GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils. Front Immunol. 2022, 13: 870183.(IF = 8.786)

8. Wang Y^#, Zhou M^#, Ye T, et al. Discovery of a Series of 5-Amide-1H-pyrazole-3-carboxyl Derivatives as Potent P2Y₁₄R Antagonists with Anti-Inflammatory. J Med Chem. 2022, 65(23): 15967-15990.

9. Dong X^#, Zhou M^#, Li Y, et al. Cardiovascular Protective Effects of Plant Polysaccharides: A Review. Front Pharmacol. 2021, 12: 783641.

10. Ye S^#, Zhou M^#, Jiang W, et al. Silencing of Gasdermin D by siRNA-Loaded PEI-Chol Lipopolymers Potently Relieves Acute Gouty Arthritis through Inhibiting Pyroptosis. Mol Pharm. 2021, 18(2): 667-678.(IF = 5.364)

Ao G^#, Zhou M^#, Li Y, et al. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents. Bioorg Med Chem. 2017, 25(1): 166-174.

(1)Discovery of therapeutic targets and drug development for liver diseases

(2) preclinical evaluation of new drugs

1、Research Projects

（1）The role of P2Y14R in deep vein thrombosis and the mechanism of targeted intervention of its lead compounds. The 72nd batch project of China Postdoctoral Science Foundation. No.2022M723513. R&D Funds: 80, 000 RMB.

（2）Design, synthesis and anti-inflammatory activity of fragment-based P2Y14 receptor antagonists. National Natural Science Foundation of China. No. 82073685. R&D Funds: 550, 000 RMB.

2、Academic Awards

(1) 2020, Research pharmacognosy academic Innovation Forum of Jiangsu province, Jiangsu Provincial Medical Postgraduate Education Steering Committee, First Prize of Provincial Ministry, 1/1.

(2)2022, Excellent Guide Teacher Award of Jiangsu Postgraduate Research Innovation and Practice Competition on “Extraction and Application of Biological Resources from Medicinal and Food Sources”, 2/2.

3、Representative Research Achievements

Ph.D Zhou has long been engaged in target discovery and new drug development for immune inflammation-related diseases. The research team has also worked closely with the Department of Medicinal Chemistry to develop novel P2Y₁₄R inhibitors based on Homology modeling and Virtual Screening, to explore candidate drugs targeting purine receptors for the treatment of inflammatory diseases. The research work on small molecule inhibitors has been published in J Med Chem, Eur J Med Chem, Int Immunopharmacol, etc. The research work has been applied for 3 invention patents and discovered several lead compounds with potential drug-forming properties, among them, 2 patents were authorized.